Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy.
Biological Specimen Banks
Brain
/ pathology
Cognitive Dysfunction
/ physiopathology
Female
Frontotemporal Lobar Degeneration
/ diagnosis
Humans
Lewy Body Disease
/ diagnosis
Male
Multiple System Atrophy
/ diagnosis
Parkinsonian Disorders
/ physiopathology
Postural Balance
/ physiology
Sensation Disorders
/ physiopathology
Sensitivity and Specificity
Supranuclear Palsy, Progressive
/ diagnosis
Tauopathies
/ diagnosis
MDS-PSP
NINDS-SPSP
PSP diagnostic criteria
progressive supranuclear palsy
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
28
10
2018
revised:
08
12
2018
accepted:
23
12
2018
pubmed:
7
2
2019
medline:
26
6
2020
entrez:
7
2
2019
Statut:
ppublish
Résumé
In 2017, the International Parkinson and Movement Disorder Society put forward new clinical criteria for the diagnosis of PSP, recognizing diverse PSP phenotypes. In this study, we compared the sensitivity and specificity of the new criteria with the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy criteria at different times. Patients with clinical parkinsonism, clinical and/or neuropathological diagnosis of PSP, were identified from the Society for Progressive Supranuclear Palsy brain bank. All patients had neuropathologic diagnoses and detailed clinical examination performed by a neurologist at 1 of the 3 Mayo Clinic sites, in Florida, Arizona, and Minnesota. Clinical symptoms and signs were abstracted retrospectively in a blinded fashion and used to determine whether patients met either diagnostic criterion. Patients were divided into early and late disease stage groups using a 3-year cutoff. A total of 129 patients were included, of whom 66 had PSP pathology (51%). The remainder had other neurodegenerative diseases. The overall sensitivity of the International Parkinson and Movement Disorder Society criteria was 87.9%, compared with 45.5% for the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy criteria, whereas the specificity of the International Parkinson and Movement Disorder Society probable PSP criteria was 85.7%, compared with 90.5% for the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy. Individual patients were noted to have features of multiple PSP phenotypes. The International Parkinson and Movement Disorder Society criteria recognize several phenotypes of progressive supranuclear palsy and hence have higher sensitivity than the previous criteria. © 2019 International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
In 2017, the International Parkinson and Movement Disorder Society put forward new clinical criteria for the diagnosis of PSP, recognizing diverse PSP phenotypes. In this study, we compared the sensitivity and specificity of the new criteria with the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy criteria at different times.
METHODS
Patients with clinical parkinsonism, clinical and/or neuropathological diagnosis of PSP, were identified from the Society for Progressive Supranuclear Palsy brain bank. All patients had neuropathologic diagnoses and detailed clinical examination performed by a neurologist at 1 of the 3 Mayo Clinic sites, in Florida, Arizona, and Minnesota. Clinical symptoms and signs were abstracted retrospectively in a blinded fashion and used to determine whether patients met either diagnostic criterion. Patients were divided into early and late disease stage groups using a 3-year cutoff.
RESULTS
A total of 129 patients were included, of whom 66 had PSP pathology (51%). The remainder had other neurodegenerative diseases. The overall sensitivity of the International Parkinson and Movement Disorder Society criteria was 87.9%, compared with 45.5% for the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy criteria, whereas the specificity of the International Parkinson and Movement Disorder Society probable PSP criteria was 85.7%, compared with 90.5% for the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy. Individual patients were noted to have features of multiple PSP phenotypes.
CONCLUSION
The International Parkinson and Movement Disorder Society criteria recognize several phenotypes of progressive supranuclear palsy and hence have higher sensitivity than the previous criteria. © 2019 International Parkinson and Movement Disorder Society.
Identifiants
pubmed: 30726566
doi: 10.1002/mds.27619
pmc: PMC6688972
mid: NIHMS1031588
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1144-1153Subventions
Organisme : NINDS NIH HHS
ID : R21 NS094684
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG038791
Pays : United States
Organisme : NIDCD NIH HHS
ID : R01 DC012519
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG041797
Pays : United States
Organisme : NINDS NIH HHS
ID : U54 NS092089
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG016574
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG052943
Pays : United States
Organisme : NIDCD NIH HHS
ID : R01 DC010367
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG006786
Pays : United States
Organisme : NIA NIH HHS
ID : R44 AG050326
Pays : United States
Organisme : NIA NIH HHS
ID : R44 AG054256
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG045390
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS089757
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS100620
Pays : United States
Organisme : NIA NIH HHS
ID : R34 AG056639
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 International Parkinson and Movement Disorder Society.
Références
Mov Disord. 2017 Jun;32(6):853-864
pubmed: 28467028
Neurology. 1996 Jul;47(1):1-9
pubmed: 8710059
Mov Disord. 2017 Jan;32(1):124-133
pubmed: 27787958
Mov Disord. 2017 Jul;32(7):955-971
pubmed: 28500751
Neurology. 1996 Apr;46(4):922-30
pubmed: 8780065
Eur J Neurol. 2012 Nov;19(11):1440-6
pubmed: 22519566
Mov Disord. 2017 Jan;32(1):134-140
pubmed: 27813160
Alzheimers Res Ther. 2017 Dec 11;9(1):96
pubmed: 29229003
Brain. 1997 Jan;120 ( Pt 1):65-74
pubmed: 9055798
Eur J Neurol. 2013 Oct;20(10):1417-22
pubmed: 23746093
Alzheimers Dement. 2013 Nov;9(6):666-76
pubmed: 23411393
Arch Neurol. 1964 Apr;10:333-59
pubmed: 14107684
Acta Neuropathol Commun. 2016 Nov 14;4(1):120
pubmed: 27842578
Neuropathol Appl Neurobiol. 2014 Feb;40(2):149-63
pubmed: 23432126
Mov Disord. 2003 Sep;18(9):1018-26
pubmed: 14502669
Brain. 2002 May;125(Pt 5):969-75
pubmed: 11960887
Arch Neurol. 1990 Jul;47(7):747-52
pubmed: 2357154
J Neuropathol Exp Neurol. 2012 Apr;71(4):266-73
pubmed: 22437338
Mov Disord. 2004 Feb;19(2):181-9
pubmed: 14978673
Neurology. 2013 Jan 29;80(5):496-503
pubmed: 23359374
Acta Neuropathol Commun. 2016 Jun 13;4(1):58
pubmed: 27296779
Mov Disord. 2018 Oct;33(10):1601-1608
pubmed: 30145797
Mov Disord. 2017 Jan;32(1):108-114
pubmed: 27709757
Neurology. 1997 Jan;48(1):119-25
pubmed: 9008506
J Neurol Neurosurg Psychiatry. 2014 Aug;85(8):925-9
pubmed: 24521567
Brain. 2011 Nov;134(Pt 11):3264-75
pubmed: 21933807
Acta Neuropathol. 2011 Aug;122(2):137-53
pubmed: 21614463
Neurology. 2011 Mar 15;76(11):1006-14
pubmed: 21325651
Brain. 2006 Jun;129(Pt 6):1385-98
pubmed: 16613895
Mov Disord. 2014 Dec;29(14):1758-66
pubmed: 25370486
Neurology. 2013 May 14;80(20):1881-7
pubmed: 23596080
Cortex. 2015 Aug;69:220-36
pubmed: 26103600
Brain. 2017 Mar 1;140(3):781-791
pubmed: 28122879
Mov Disord. 2016 May;31(5):653-62
pubmed: 26841329
Brain. 2018 Jul 1;141(7):2181-2193
pubmed: 29878075
JAMA Neurol. 2016 Jun 1;73(6):733-42
pubmed: 27111692
Neuropathol Appl Neurobiol. 2016 Feb;42(1):6-19
pubmed: 26750431
Neurology. 2006 Jan 10;66(1):41-8
pubmed: 16401843
J Neurol. 2016 Dec;263(12):2419-2423
pubmed: 27624121
Neurocase. 2005 Aug;11(4):283-96
pubmed: 16093229
Curr Opin Neurol. 2008 Dec;21(6):688-92
pubmed: 18989114
Parkinsonism Relat Disord. 2014 May;20(5):525-9
pubmed: 24637124
J Neural Transm Suppl. 1994;42:15-31
pubmed: 7964684
Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S34-6
pubmed: 26421392
Alzheimer Dis Assoc Disord. 2007 Oct-Dec;21(4):S14-8
pubmed: 18090417
Nat Rev Neurol. 2011 May;7(5):263-72
pubmed: 21487420
Acta Neuropathol. 2018 Sep;136(3):389-404
pubmed: 29926172
J Neuropathol Exp Neurol. 1996 Jan;55(1):97-105
pubmed: 8558176
J Mol Neurosci. 2011 Nov;45(3):384-9
pubmed: 21720721
J Neurol. 1999 Sep;246 Suppl 2:II6-15
pubmed: 10525997